Supplementary Table – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
收藏数据链接：
官方服务：
资源简介：
Supplementary Table 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status The reasons for dose reduction
创建时间：
2021-11-11
